

Cell Type-Selective, Potent Signaling Pathway Modulation Using A Guide-Effector Bispecific Design

Tech ID: 34519 / UC Case 2017-049-0

VALUE PROPOSITION

In targeting strategies for bispecific antibodies toxicity is a concern as both antibodies in some cases bind to signaling receptors critical for cell growth and survival. Approaches that allow modular development of bispecific antibodies with a goal of achieving maximum effect on a target cell (e.g. tumor) but no or minimum effect on normal cells would greatly improve the safety of new bispecific antibody therapeutics.

TECHNOLOGY DESCRIPTION

UCSF investigators have engineered bispecific antibodies and have demonstrated their anti-tumorigenic activities in vitro even in cases where the density ratio of the guide antigen to the effector antigen is high.

PATENT STATUS

Country	Type	Number	Dated	Case
China	Issued Patent	ZL201780083549.3	05/24/2024	2017-049
United States Of America	Issued Patent	11,702,480	07/18/2023	2017-049
United States Of America	Published Application	20240076399	03/07/2024	2017-049
European Patent Office	Published Application	3541423	09/25/2019	2017-049

CONTACT

Kristin A. Agopian
kristin.agopian@ucsf.edu
 tel: 415-340-2619.



OTHER INFORMATION

KEYWORDS

bispecific, antibody, oncology

CATEGORIZED AS

- ▶ **Biotechnology**
- ▶ Health
- ▶ **Medical**
- ▶ Disease: Cancer
- ▶ New Chemical Entities, Drug Leads
- ▶ Therapeutics

RELATED CASES

2017-049-0

ADDRESS

UCSF

Innovation Ventures

600 16th St, Genentech Hall, S-272,
 San Francisco, CA 94158

CONTACT

Tel:

innovation@ucsf.edu

<https://innovation.ucsf.edu>

Fax:

CONNECT

 Follow  Connect

© 2026, The Regents of the University of California

[Terms of use](#) [Privacy Notice](#)

